Single-dose pharmacokinetics, pharmacodynamics, tolerability and safety of dabigatran etexilate in infants under 1 year at the end of standard anticoagulant therapy

Phase 2, open-label, single-arm trial of dabigatran in venous thromboembolism (VTE) and Phlebothrombosis, sponsored by Boehringer Ingelheim. Primary endpoints: Total dabigatran plasma concentration at 2 hours post dose and Total dabigatran plasma concentration at 12 hours post dose. Started Jul 2014; status: completed.